Humacyte (HUMA) Net Margin (2020 - 2026)
Humacyte (HUMA) reported Net Margin of 6237.58% for Q1 2026, down 129792.0% year-over-year from N/an in Q1 2025, and up 12.85% quarter-over-quarter from 7157.6% in Q4 2025.
Humacyte (HUMA) Net Margin (2020 - 2026) Analysis & Trends
Humacyte (HUMA) has 4 years of Net Margin data on file, last reported at 6237.58% in Q1 2026.
- Net Margin for Q1 2026 came in at 6237.58%, down 129792.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 6059.23% (up 1671795.0% YoY), and the FY2025 annual result was 5731.11%, changed N/A from the prior year.
- Net Margin climbed to 6237.58% in Q1 2026 per HUMA's latest filing, from 7157.6% in the prior quarter.
- Over five years, Net Margin peaked at 3507.57% in Q3 2025 and troughed at 10445.18% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | 0.82% |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 34.53% |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | - |
| 10 | Humacyte | 267.09 Mn | 218.55 Mn | -1.54 Mn | -6,237.58% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6,237.58% |
| Dec 31, 2025 | -7,157.60% |
| Sep 30, 2025 | -3,507.57% |
| Jun 30, 2025 | -10,445.18% |
| Mar 31, 2025 | -4,939.65% |
| Sep 30, 2021 | -9,022.41% |
| Sep 30, 2020 | -1,943.11% |